ClearPoint Neuro WKN: A2PZ3E ISIN: US18507C1036 Kürzel: CLPT Forum: Aktien Thema: Hauptdiskussion
Anzeige
5,14 USD
+0,59 %+0,03
23. Sep, 02:00:00 Uhr,
Nasdaq
Kommentare 87
Summer.76,
09.11.2022 5:40
0
ClearPoint Neuro Reports Third Quarter 2022 Results
https://www.globenewswire.com/news-release/2022/11/08/2551424/25687/en/ClearPoint-Neuro-Reports-Third-Quarter-2022-Results.html
Company Reaffirms 2022 Revenue Forecast
Summer.76,
09.11.2022 5:40
1
ClearPoint Neuro GAAP EPS of -$0.15, revenue of $5.1M
https://seekingalpha.com/news/3904123-clearpoint-neuro-gaap-eps-of-0_15-revenue-of-5_1m
• ClearPoint Neuro press release (NASDAQ:CLPT): Q3 GAAP EPS of -$0.15. Revenue of $5.1M vs $4.6M.
• CLPT reaffirmed full year 2022 revenue outlook of between $21.0 and $22.0M.
• Cash and short-term investments totaled $40.5M as of Sept 30, 2022.
• CLPT said three new products were cleared by FDA in the quarter and are in the process of being deployed in limited market releases before the end of the year.
• "We achieved another strong quarter for revenue despite a historically high case cancellation rate and hospital supply chain disruptions." - President and CEO Joe Burnett
Summer.76,
12.12.2022 17:20
0
https://www.globenewswire.com/news-release/2022/12/12/2571981/0/en/ClearPoint-Neuro-Announces-First-Patient-Enrolled-in-Glioblastoma-Trial-Using-ClearPoint-Prism-Neuro-Laser-Therapy-System-at-Sk%C3%A5ne-University-Hospital-in-Sweden.html
Summer.76,
11.01.2023 15:17
0
https://www.globenewswire.com/news-release/2023/01/11/2587014/25687/en/ClearPoint-Neuro-Reports-Fourth-Quarter-and-Full-Year-2022-Preliminary-Revenue-Results-and-Guidance-for-Full-Year-2023-Revenue.html
Summer.76,
23.09.2022 12:13
0
https://www.globenewswire.com/news-release/2022/09/23/2521573/0/en/ClearPoint-Neuro-Announces-FDA-Clearance-for-ClearPoint-Prism-Neuro-Laser-Therapy-System.html
Summer.76,
20.09.2022 6:27
0
https://www.globenewswire.com/news-release/2022/09/19/2518720/0/en/ClearPoint-Neuro-Announces-FDA-Clearance-for-Software-Version-2-1.html
Summer.76,
10.08.2022 5:52
0
ClearPoint Neuro Announces FDA Clearance for ClearPoint Maestro™ Brain Model
https://www.globenewswire.com/news-release/2022/08/09/2495317/25687/en/ClearPoint-Neuro-Announces-FDA-Clearance-for-ClearPoint-Maestro-Brain-Model.html
Summer.76,
10.08.2022 5:52
0
ClearPoint Neuro, Inc. Misses Q2 EPS by 16c
https://m.investing.com/news/clearpoint-neuro-inc-misses-q2-eps-by-16c-432SI-2868428?ampMode=1
Summer.76,
03.06.2022 5:49
0
https://www.globenewswire.com/news-release/2022/06/02/2455609/25687/en/ClearPoint-Neuro-Announces-Receipt-of-MDSAP-Certification.html
Summer.76,
20.05.2022 15:48
0
ClearPoint Neuro Congratulates Partner PTC Therapeutics on Receiving Positive CHMP Opinion for Gene Therapy to Treat AADC Deficiency
https://www.globenewswire.com/news-release/2022/05/20/2447753/0/en/ClearPoint-Neuro-Congratulates-Partner-PTC-Therapeutics-on-Receiving-Positive-CHMP-Opinion-for-Gene-Therapy-to-Treat-AADC-Deficiency.html
First Gene Therapy Directly Infused into the Brain to be Administered with ClearPoint’s SmartFlow® Cannula
Summer.76,
12.05.2022 16:54
0
https://www.fool.com/earnings/call-transcripts/2022/05/11/clearpoint-neuro-inc-clpt-q1-2022-earnings-call-tr/
Summer.76,
12.05.2022 5:27
0
ClearPoint Neuro Reports First Quarter 2022 Results
https://www.globenewswire.com/news-release/2022/05/11/2441245/25687/en/ClearPoint-Neuro-Reports-First-Quarter-2022-Results.html
Summer.76,
04.05.2022 17:30
0
https://www.globenewswire.com/news-release/2022/05/03/2435061/25687/en/ClearPoint-Neuro-and-Higgs-Boson-Health-Announce-Collaboration.html
Summer.76,
29.04.2022 5:46
0
ClearPoint Neuro Announces FDA Clearance of the SmartFrame Array™ Version 1.1
https://www.globenewswire.com/news-release/2022/04/28/2431949/0/en/ClearPoint-Neuro-Announces-FDA-Clearance-of-the-SmartFrame-Array-Version-1-1.html
Next Generation Neuro Navigation System Designed for Use in Both the MRI Suite and Operating Room
Summer.76,
28.04.2022 6:37
0
ClearPoint Neuro Expands Software License and Research Agreement with Philips to Power Expansion of the ClearPoint Platform into the Operating Room
https://www.globenewswire.com/news-release/2022/04/27/2430700/25687/en/ClearPoint-Neuro-Expands-Software-License-and-Research-Agreement-with-Philips-to-Power-Expansion-of-the-ClearPoint-Platform-into-the-Operating-Room.html
Meistdiskutiert
|
Thema | ||
---|---|---|---|
1 | BED BATH & BEYOND Hauptdiskussion | -13,04 % | |
2 | Aktien und Saunaclub alla Luci | ||
3 | für alle, die es ehrlich meinen beim Traden. | ||
4 | BRAINCHIP HOLDINGS LTD Hauptdiskussion | -1,15 % | |
5 | Nantkwest / Immunitybio -> IBRX | +0,92 % | |
6 | SOFI - Social Finance | -5,16 % | |
7 | T2 Bio Systems | -12,35 % | |
8 | BALLARD POWER Hauptdiskussion | -4,45 % | |
9 | MEDICAL PROPERTIES Hauptdiskussion | +0,56 % | |
10 | SMA SOLAR Hauptdiskussion | -0,04 % | Alle Diskussionen |
Aktien
|
Thema | ||
---|---|---|---|
1 | BED BATH & BEYOND Hauptdiskussion | -13,04 % | |
2 | BRAINCHIP HOLDINGS LTD Hauptdiskussion | -1,15 % | |
3 | Nantkwest / Immunitybio -> IBRX | +0,92 % | |
4 | SOFI - Social Finance | -5,16 % | |
5 | BALLARD POWER Hauptdiskussion | -4,45 % | |
6 | SMA SOLAR Hauptdiskussion | -0,04 % | |
7 | MUTARES Hauptdiskussion | +6,04 % | |
8 | UNITEDHEALTH GROUP Hauptdiskussion | +1,04 % | |
9 | BYD Hauptdiskussion | +3,35 % | |
10 | LATIN RESOURCES LTD Hauptdiskussion | +6,35 % | Alle Diskussionen |
Werbung
Ihre kurzfristige Erwartung an CLPT
Veränderung:
mgl. Rendite mit
Hebel (Omega)
Zum Produkt